Psychiatr. pro Praxi, 2008; 9(4): 185-186

Sertindol se vrací

MUDr. Klára Látalová Ph.D
Psychiatrická klinika FN a LF UP, Olomouc

Sertindol je antipsychotikum druhé generace, které se vyznačuje silnou blokádou serotoninových S2, dopaminových D2 a adrenalinových α1-receptorů. Nevykazuje nežádoucí anticholinergní a antihistaminové účinky. Nezpůsobuje extrapyramidové vedlejší příznaky. Byl stažen z trhu z důvodu prodlužování QT intervalu a záznamů o náhlých úmrtích na srdeční atytmie. Jeho užití je znovu povoleno poté, co se ukázalo, že epidemiologická data nejsou spolehlivě doložena.

Keywords: Klíčová slova: sertindol, antipsychotika druhé generace.

Published: November 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Látalová K. Sertindol se vrací. Psychiatr. praxi. 2008;9(4):185-186.
Download citation

References

  1. Azorin JM, Strub N, Loft H. Sertindole is well tolerated and demonstrates efficacy advantages over risperidone in the treatment of moderate-to severe schizophrenia. Int. Clin. Psychopharmacol. 2006; 21: 49-56. Go to original source... Go to PubMed...
  2. Gallhofer B, Jaanson P, Mittoux AS, Tanghoj P, Lis S, Krieger S. Course of recovery of cognitive impairment in patients with schizophrenia: A randomized double-blind study comparing sertindole and haloperidol. Pharmacopsychiatry 2007; 40: 275-286. Go to original source... Go to PubMed...
  3. Moore N. Higher cardiovascular mortality with sertindole in ADROIT: a signal not confirmed. Internat. J. Psychiatry in Clinical Practice 2002; 6(suppl. 1): S3-S9. Go to original source... Go to PubMed...
  4. Muldoon C, Cochran J. Mortality rates in three comparative cohorts of patients who received sertindole, olanzapine or risperidone: a hospital-based, retrospective study. J. Outcomes Research 2006; 10: 47-55.
  5. Nyberg S, Olsson U, Nilsson E, Maehlum A, Halldin C, Farde L. Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole. Psychopharmacology 2002; 162: 37-41. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.